Literature DB >> 25601422

Oral erythromycin therapy in epidermolysis bullosa simplex generalized severe.

C Chiaverini1,2, E Fontas3, P Vabres4, D Bessis5, J Mazereeuw6, A Charlesworth7,8, G Meneguzzi8, J-P Lacour7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25601422     DOI： 10.1111/bjd.13672

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  4 in total

Review 1.  Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Authors:  Verena Wally; Manuela Reisenberger; Sophie Kitzmüller; Martin Laimer
Journal:  Orphanet J Rare Dis       Date:  2020-10-19       Impact factor: 4.123

2.  A Novel Mutation p.L461P in KRT5 Causing Localized Epidermolysis Bullosa Simplex.

Authors:  Xin Jiang; Yingyu Zhu; Huihui Sun; Feng Gu
Journal:  Ann Dermatol       Date:  2020-12-30       Impact factor: 1.444

3.  Cut and Paste: Efficient Homology-Directed Repair of a Dominant Negative KRT14 Mutation via CRISPR/Cas9 Nickases.

Authors:  Thomas Kocher; Patricia Peking; Alfred Klausegger; Eva Maria Murauer; Josefina Piñón Hofbauer; Verena Wally; Thomas Lettner; Stefan Hainzl; Michael Ablinger; Johann Wolfgang Bauer; Julia Reichelt; Ulrich Koller
Journal:  Mol Ther       Date:  2017-08-24       Impact factor: 11.454

4.  Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.

Authors:  Michael Ablinger; Thomas K Felder; Monika Wimmer; Roland Zauner; Peter Hofbauer; Thomas Lettner; Martin Wolkersdorfer; Florian B Lagler; Anja Diem; Johann W Bauer; Verena Wally
Journal:  Orphanet J Rare Dis       Date:  2018-11-01       Impact factor: 4.123
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.